Plasma tau-species-containing neuron-derived extracellular vesicles as potential biomarkers for progressive supranuclear palsy
Objective: This study aimed to develop and validate novel plasma PSP biomarkers based on tau-species-containing neuron-derived extracellular vesicles (NDEVs) in two independent cohorts (discovery and…Clinical Deficits, Quality of Life and Caregiver Burden across PSP Phenotypes
Objective: To assess clinical deficits, quality of life and caregiver burden across progressive supranuclear palsy (PSP) phenotypes considering also other variables such as age, sex…Neuropsychiatric profile of progressive supranuclear palsy phenotypes
Objective: To analyze neuropsychiatric symptoms among phenotypes of patients with Progressive supranuclear palsy (PSP) in movement disorder centers in Colombia and Mexico. Background: Progressive supranuclear…4R-TAU seed amplification assay discriminates tauopathies from non-tauopathies and CBD from PSP in post-mortem brain samples
Objective: To investigate whether 4R-TAU seed amplification assay discriminates tauopathies from non-tauopathies as well as CBD from PSP in post-mortem brain samples. Background: 4 repeat…Integrated Management of atypical Parkinsonism: A home-based patient-Centered healthcare model using Telenursing. Baseline data from the Multicentre IMPACT study
Objective: To evaluate the effectiveness of a telemedicine-based (‘Telenursing’) home healthcare model, coordinated by a Parkinsonism Nurse Specialist (PKNS), in improving the quality of life…An Interesting Case of Oculo-Palatal-Pharyngeal Tremor
Objective: We present a case report of a 59 year old with a diagnosis of clinically possible progressive supranuclear palsy (PSP) and clinical finding of…Neuroinflammatory response is determined by HLA genotype in progressive supranuclear palsy
Objective: Our aim was to examine whether the HLA haplotypes influence the neuroinflammatory response in a cohort of neuropathologically diagnosed PSP cases. Background: Progressive supranuclear…Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS)
Objective: The NORAPS phase II study (ISRCTN99462035) investigates the safety, tolerability and efficacy of atomoxetine in Progressive Supranuclear Palsy (PSP). Background: PSP is a neurodegenerative…Validation of the Short Progressive Supranuclear Palsy Quality of Life Scale in PSPNI
Objective: This study aimed to evaluate the reliability, validity, and sensitivity to change of the PSP-ShoQoL in PSPNI, a longitudinal Chinese PSP cohort. Background: Self-reported…Quantitative Regional Tau Pathology and Spatial Transcriptomics Identify Signatures of Phenotypic Diversity in Progressive Supranuclear Palsy.
Objective: To determine the pathological and molecular determinants of phenotypic diversity in PSP. Background: PSP exhibits broad variability in clinical phenotype and progression, however the…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 49
- Next Page »